Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Apellis Pharmaceuticals Inc (NASDAQ: APLS) today and set a price target of $40. The company’s shares opened today at $19.52.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 14.3% and a 58.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Apellis Pharmaceuticals Inc is a Strong Buy with an average price target of $40, representing a 104.9% upside. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $53 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32 and a one-year low of $12.45. Currently, Apellis Pharmaceuticals Inc has an average volume of 374.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product.
